N,N-Dimethyltryptamine (DMT)
GPTKB entity
Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
alkaloid
Hallucinogen |
| gptkbp:appearance |
white to yellowish crystalline solid
|
| gptkbp:boilingPoint |
160 °C (at 0.2 mmHg)
|
| gptkbp:CASNumber |
61-50-7
|
| gptkbp:chemicalFormula |
C12H16N2
|
| gptkbp:discoveredBy |
Richard Manske
|
| gptkbp:discoveredIn |
1931
|
| gptkbp:drugClass |
serotonin receptor agonist
|
| gptkbp:duration |
5–30 minutes (inhaled)
2–6 hours (oral with MAOI) |
| gptkbp:effect |
mystical experiences
hallucinations altered perception of time |
| gptkbp:excretion |
urine
|
| gptkbp:featuredIn |
book 'DMT: The Spirit Molecule' by Rick Strassman
documentary 'DMT: The Spirit Molecule' |
| gptkbp:hasInChIKey |
KXANITVJZQZKSG-UHFFFAOYSA-N
|
| gptkbp:hasSMILES |
CN(C)CCc1c[nH]c2cccc(C1)2
|
| https://www.w3.org/2000/01/rdf-schema#label |
N,N-Dimethyltryptamine (DMT)
|
| gptkbp:IUPACName |
2-(1H-indol-3-yl)-N,N-dimethylethanamine
|
| gptkbp:legalStatus |
gptkb:Schedule_III_(Canada)
gptkb:Schedule_I_(US) gptkb:Class_A_(UK) Schedule 9 (Australia) |
| gptkbp:mainStreet |
gptkb:Dimitri
the spirit molecule |
| gptkbp:mechanismOfAction |
5-HT2A receptor agonist
|
| gptkbp:meltingPoint |
44–46 °C
|
| gptkbp:metabolism |
gptkb:indole-3-acetic_acid
liver |
| gptkbp:molecularWeight |
188.27 g/mol
|
| gptkbp:naturalOccurrence |
some animals
many plants |
| gptkbp:notableFor |
component of ayahuasca
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL39122
gptkb:DB01486 6089 CHEBI:4610 |
| gptkbp:relatedTo |
gptkb:5-MeO-DMT
gptkb:bufotenin psilocybin |
| gptkbp:researchInterest |
consciousness studies
psychedelic therapy |
| gptkbp:riskFactor |
confusion
nausea psychological distress vomiting anxiety hypertension tachycardia |
| gptkbp:routeOfAdministration |
inhalation
intramuscular injection oral (with MAOI) |
| gptkbp:toxicity |
low acute toxicity
|
| gptkbp:traditionalUse |
South American shamanic rituals
|
| gptkbp:UNII |
WUB6018FEM
|
| gptkbp:bfsParent |
gptkb:Rick_Strassman
|
| gptkbp:bfsLayer |
7
|